Caplin Point Steriles Scores USFDA Win: Linezolid Injection Bags Approved

Approval Milestone

Caplin Point Laboratories Ltd (NSE: CAPLIPOINT) announced on December 9, 2025, that its wholly-owned unit Caplin Steriles secured final USFDA nod for Abbreviated New Drug Application (ANDA) of Linezolid Injection in infusion bags. Linezolid, a critical antibiotic for resistant infections, aligns with Caplin's aggressive US expansion via sterile injectables. This approval enhances the company's 40+ USFDA nods, building on recent successes in ophthalmics and emulsions.

Key Highlights

Product Specs: Generic equivalent for nosocomial pneumonia, VRE infections; targets $200M+ US market (IQVIA data); available in ready-to-use infusion bags for hospital efficiency.

Strategic Fit: Caplin Steriles' Gummidipoondi facility (zero 483 observations) supports 52 ANDAs filed, 42 approved; focuses on high-barrier injectables.

Growth Impact: US revenue potential surges; YTD stock up 15%, P/E 28x; complements prior approvals like Levetiracetam, Phytonadione.

Market Context: Addresses antibiotic resistance crisis; peers like Lupin hold Zyvox generics, but infusion format differentiates Caplin.

Sources: Caplin Point website, USFDA listings, IQVIA data